RecruitingNot ApplicableNCT06648278

Patient Care Outreach, Navigation, Technology and Support 2.0

The Patient Care Outreach, Navigation, Technology and Support 2.0 Study

Sponsor

University of California, San Francisco

Enrollment

260 participants

Start Date

Aug 10, 2023

Study Type

INTERVENTIONAL

Conditions

Breast Cancer Cardiovascular Diseases

Summary

This is a feasibility study employing virtual patient navigation for underserved individuals who speak English, Chinese or Spanish and were diagnosed with breast cancer or cardiovascular disease to determine the extent of usability for a virtual patient navigation portal serving people in underserved communities. While not able to entirely replace in-person interactions, virtual patient navigation may be used to expand reach and availability of navigation services to a much greater segment of the population.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a digital patient navigation program designed to help underserved breast cancer patients — including those who speak English, Mandarin/Cantonese, or Spanish — access care and support through an online portal and text message check-ins. **You may be eligible if...** - You are 18 or older - You have been diagnosed with any stage of breast cancer - You speak English, Mandarin/Cantonese, or Spanish - You have a phone capable of receiving text messages - You are willing to participate for 6–7 months **You may NOT be eligible if...** - You have a medical or psychological condition that would prevent you from safely participating Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALPatient Navigation Program

Online health tool

OTHERQuality-of-Life (QOL) Assessment

Online surveys to assess QOL

OTHERSurvey Administration

Ancillary studies

Locations(2)

Zuckerberg San Francisco General Hospital

San Francisco, California, United States

University of California, San Francisco

San Francisco, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06648278

Related Trials

Acute Impact of Whey Protein-enriched Milk Fat Globule Membrane Supplementation on Postprandial Markers of Heart and Brain Health

NCT069532321 location

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

NCT072146624 locations

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT06790693226 locations

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

NCT058799261238 locations

A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

NCT07062965384 locations